Analyst Justin Walsh Reaffirms Buy on TriSalus After Strong Q2 Results, CMS Reimbursement Tailwinds, and Growth Outlook Through 2026Tip Ranks·2 days ago, 11:25 AMTLSI-0.52%
TriSalus Life Sciences | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 11.41 MEarnings Watch·Aug 6 at 03:15 PMTLSI-0.52%
TriSalus Q2 FY26 net loss narrows 40.74% to $0.16 per share; revenue rises 1.7% to $11.4 millionPUBT·Aug 6 at 03:11 PMTLSI-0.52%
TriSalus Life Sciences to join Canaccord Genuity Annual Growth Conference fireside chatPUBT·Jul 29 at 03:13 PMTLSI-0.52%
TriSalus Life Sciences names Richard Henry Marshall as chief medical officer in initial beneficial ownership filingPUBT·Jun 29 at 03:31 PMTLSI-0.52%
12:08 ETTLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firmprnewswire·Jun 8 at 11:09 AMTLSI-0.52%
TLSI (TLSI) Securities Fraud Investigation - Levi & KorsinskyUnusual Whales·May 22 at 08:03 AMTLSI-0.52%
TriSalus Leaders Quietly Make a Bold Bet on the Company’s FutureTip Ranks·May 18 at 09:16 PMTLSI-0.52%
19:02 ETTLSI Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of TLSI (TLSI)prnewswire·May 15 at 06:03 PMTLSI-0.52%
U.S. stock night market volatility: TriSalus Life Sciences' earnings report exceeded expectations but revenue declined, and analyst ratings failed to boost the stock price, falling by 3.57%Price Alert·May 14 at 07:31 PMTLSI-0.52%
